P
Prime Medicine
Was founded to bring the promise of gene editing to patients
About Prime Medicine
Prime Medicine is a pioneering biotech startup focused on revolutionizing the field of gene editing. The company leverages a cutting-edge technology called Prime Editing, which allows for precise modifications to DNA. This technology can locate and correct faulty segments of DNA, thereby restoring normal genetic function. The ultimate goal of Prime Medicine is to cure, halt, or even prevent genetic diseases, offering lifelong benefits to patients.
Read full description
Prime Medicine primarily serves patients suffering from genetic disorders, a market that includes millions of individuals worldwide. The company operates in the rapidly growing biotech and healthcare sectors, where advancements in gene editing are poised to make significant impacts.
The business model of Prime Medicine is centered around the development and commercialization of its Prime Editing technology. The company collaborates with various partners, including research institutions and pharmaceutical companies, to advance its technology and bring it to market. Revenue is generated through licensing agreements, partnerships, and potentially future sales of gene-editing therapies.
Prime Medicine's leadership team includes industry veterans with extensive experience in process development and manufacturing of innovative medicines. The recent appointment of Ann L. Lee as Chief Technical Officer underscores the company's commitment to advancing its technological capabilities and scaling its operations.
In summary, Prime Medicine is at the forefront of gene editing technology, aiming to transform the treatment of genetic diseases through its innovative Prime Editing platform.
At a glance
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Listing
- IPO 2022
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Prime Medicine.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cystic Fibrosis Foundation
Series A5 investors entered at this stage
F-Prime
Newpath Partners
ARCH Venture Partners- ANArrive Roc Nation
Casdin Capital
Series B and later2 investors entered at this stage
- MTMassachusetts Institute of Technology
- Casdin Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
28 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Prime Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prime Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.